BiotechTube
Home/Pipeline/MOTO-CAR Immunotherapy

MOTO-CAR Immunotherapy

Solid Tumors

Pre-clinicalActive

Key Facts

Indication
Solid Tumors
Phase
Pre-clinical
Status
Active
Company
Thunder Biotech

About Thunder Biotech

Thunder Biotech is an early-stage biotech firm pioneering CAR-macrophage (MOTO-CAR) immunotherapy for solid tumors. Founded in 2020 and led by its scientific founder, Dr. Kim O'Neill, the company is in the pre-clinical development stage and is privately funded. It aims to disrupt traditional cancer treatment norms by leveraging engineered macrophages to induce long-term anti-tumor immunity, targeting a significant unmet need in oncology.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

DrugCompanyPhase
APVO603Aptevo TherapeuticsPreclinical
APVO711Aptevo TherapeuticsPreclinical
Platform-derived ImmunotherapyGenCirqPre-clinical
SP-2-225Shuttle PharmaceuticalsPreclinical
SP-1-161Shuttle PharmaceuticalsPreclinical
HBM1020Harbour BioMedPhase 1
HBM7022Harbour BioMedPhase 1
HBM9033Harbour BioMedDiscovery
Undisclosed Whole Cell Vaccine Program(s)NeuvogenPre-clinical
SY-5609Syros PharmaceuticalsPhase 1/2
Not Specified (TCR Therapy)T-Cure BiosciencePhase 1
B7-H3 ProgramOcean BiomedicalDiscovery